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Chronic liver diseases or liver injuries commonly result
in increased intrahepatic resistance and subsequently
lead to portal hypertension. Portal hypertension is asso-
ciated with 2 distinct pathophysiologic features: hyper-
dynamic circulation and formation of portal-systemic
collaterals.1 Hyperdynamic circulation is characterized
by increased splanchnic blood flow, cardiac output,
decreased systemic arterial blood pressure and low
peripheral vascular resistance. The formation of portal-
systemic collaterals is manifested by the appearance of
esophageal or gastric varices. These collateral vessels will
shunt part of the portal blood flow bypassing the liver
to systemic circulation. Shunting the portal blood flow
through collateral vessels is an attempt to decompress
the highly pressurized portal system. However, the for-
mation of collateral vessels may lead to serious clinical
events such as variceal rupture and bleeding, which car-
ries a high risk of morbidity and mortality. Therefore,
revealing the mechanism underlying the development
of portal-systemic collaterals is an important issue and
has been extensively investigated in recent years.
Both non-cirrhotic and cirrhotic models of portal
hypertension have been extensively used in studies of
the pathophysiology of portal hypertension and portal-
systemic collaterals. The partial portal vein ligation
(PVL) model has been widely used in the study of
portal hypertension due to its reproducibility and being
easy to perform. In the PVL model, portal-systemic
collaterals can be detected as early as 2 days and develop
fully after 1 week. The degree of shunting is very high
and may approach 100%. The main drawback of the
PVL model is that, contrary to the usual clinical situa-
tion, portal hypertension will gradually decrease after
the establishment of portal-systemic collaterals. Thus,
cirrhotic models of portal hypertension are closer to the
real pathophysiology of cirrhotic patients in clinical
practice. Cirrhotic models of portal hypertension are
commonly induced by common bile duct ligation
(CBDL), or liver toxins such as carbon tetrachloride
and thioacetamide. In these models, the degrees of
portal-systemic shunting developed gradually by time
of liver injury and varied widely from less than 30% 
up to 60%, and were generally lower than in the PVL
model.
Progress in understanding the pathophysiology
and pharmacology of portal-systemic collaterals relies
greatly on the technique of in situ perfusion of collateral
circulation developed by Mosca et al in 1992.2 They
showed in PVL rats that several vasoactive substances
produce direct vasodilatory or vasoconstrictory effects
on collaterals. In addition, different types of receptors
including α-receptor, β-receptor and 5-hydroxytrypt-
amine receptors were expressed on the endothelium of
collaterals vessels. Subsequently, using this technique,
it has been demonstrated that arginine vasopressin and
endothelin-1 (ET-1), as well as nitric oxide (NO) and
prostaglandins, are able to modulate the vascular activity
of portal-systemic collaterals.3,4 Also, the non-vasoactive
agents, somatostatin and octreotide, which are now
widely used in the treatment of variceal bleeding,
enhanced the vasoconstrictive effect of ET-1 on collat-
eral vascular beds.5 In 2004, this technique was mod-
ified and transferred successfully to CBDL rats to study
the portal-systemic collaterals of cirrhotic rats. Simi-
larly, as in PVL rats, there are many vasoactive factors
involved in the regulation of collateral blood flow in
cirrhotic rats even though there was less shunting.
These results indicate that the portal-systemic collat-
erals are not simply a route to bypass the liver, but
they are dynamic vascular beds that respond to many
regulators.
The underlying mechanisms of the development of
portal-systemic collaterals remain undetermined. On
the one hand, it has been proposed that development of
portal-systemic collaterals is a process of NO-mediated
dilatation of pre-existing vessels.1 NO is the main
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endothelial vasodilator. Chronic administration of 
L-NAME, a non-selective inhibitor of NO synthase,
significantly decreased the degree of shunting, i.e. the
formation of portal-systemic collaterals.6 On the other
hand, the development of portal-systemic collaterals
in portal hypertension has been associated with the
activation process of angiogenesis.7 Several chemicals
or cytokines which increased early in the portal hyper-
tensive stage are reported to be factors involved in
angiogenesis. These factors include NO, carbon monox-
ide and tumor necrosis factor-α. Growth factors such
as basic fibroblast growth factor, vascular endothelial
growth factor (VEGF) and platelet-derived growth
factor (PDGF) have also been shown to be important
mediators of angiogenesis. Among them, VEGF and
VEGF receptor-2 seem to be the major mediators in
angiogenesis.8
An anti-angiogenic approach by targeting the VEGF
or PDGF pathway is a new therapeutic strategy for the
treatment of portal hypertension. Recently, researchers
have performed several foresighted studies with excit-
ing results. It has been demonstrated in portal hyper-
tensive animals that chronic inhibition of VEGF and
PDGF signaling significantly reduced the degree of
shunting.9 However, despite reducing the formation
of portal-systemic collaterals, VEGF blockade will not
always concomitantly reduce portal pressure. Simi-
larly, in the study of Chang et al, chronic thalidomide
treatment enhanced the collateral vasoconstrictive
response to vasopressin without changing portal and
systemic hemodynamics.10 Thalidomide, known to be
teratogenic and previously banned from use, is regain-
ing much attention due to its anti-inflammatory, anti-
proliferative and anti-angiogenic effects, as well as its
immunomodulatory activity. In recent years, thalido-
mide and its derivative have been vigorously investi-
gated in anti-cancer therapy.11 It is worth noting in
Chang et al’s study that thalidomide effectively reduced
the plasma level of VEGF in cirrhotic rats. These find-
ings may imply that the angiogenic process in portal-
systemic collaterals of portal hypertension does not
necessarily require the pressure-derived stimulus from
portal tributary. Neovascularization of portal-systemic
collaterals occurs continuously and anti-angiogenic
therapy is possible even in the advanced stage.
There are other issues focusing on angiogenesis that
deserve further investigation in portal-systemic collat-
erals. The initiation of vascular proliferation requires
signal communication between endothelial cells and
smooth muscle cells across the vessel wall. At present,
the interactions between collateral endothelial cells,
smooth muscle cells and the extracellular matrix
remain unclear. How do the circulating VEGF and
other growth factors or cytokine transmit the signals
to initiate angiogenesis? Where and how are the sig-
nals processed and passed down to the effecter cells?
Solving this complicated mechanism of cell–cell and
cell–matrix interactions will help us better understand
the pathophysiology of portal-systemic collaterals 
and develop more effective anti-angiogenic therapy for
portal hypertension in the future.
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